News : ConnCons GmbH closes seed financing round for the development of intelligent medical infusion systems.

Logo ConCons
ConnCons GmbH is the spin-off of a team of high-tech specialists together with Prof. Dr. med. Jochen Hampe, Director of the Medical Clinic and Polyclinic I at the University Hospital of the TU Dresden. In the interprofessional team, engineers and computer scientists work hand in hand with physicians, pharmacists, and nursing staff to create connectivity across the board.

Conn­Cons GmbH deve­lops net­worked medi­cal infu­sion sys­tems. By inte­gra­ting a digi­tal infra­struc­ture, all com­pon­ents of the infu­sion sys­tem are con­nec­ted to digi­tal plan­ning and moni­to­ring sys­tems. This seam­less con­nec­tion of the­rapy plan­ning, drug pre­pa­ra­tion and admi­nis­tra­tion pre­vents errors due to manual pro­ces­ses and trans­fers bet­ween sys­tems. In addi­tion, it forms the basis for the auto­ma­tion of highly repe­ti­tive acti­vi­ties, because the com­plex the­rapy pro­ces­ses curr­ently require a high degree of manual coor­di­na­tion and docu­men­ta­tion. As a result, medi­cal staff are over­worked and often frus­tra­ted by the high num­ber of indi­vi­dual mea­su­res. Among other things, this leads to increased risk of medi­ca­tion errors, high staf­fing costs, and a sub­op­ti­mal tre­at­ment expe­ri­ence for pati­ents and medi­cal teams.

The goal of Conn­Cons GmbH is to auto­mate the mar­ket in the field of digi­tal con­trol of, among other things, medi­cal fluid the­ra­pies and thus to gene­rate a com­pe­ti­tive advan­tage that should lead to a signi­fi­cant mar­ket share in an eco­no­mic­ally attrac­tive seg­ment. Conn­Cons GmbH’s plat­form solu­tion crea­tes over­ar­ching con­nec­ti­vity inde­pen­dent of the digi­tiza­tion of the sur­roun­ding health­care structures.

Conn­Cons will be accom­pa­nied by the inves­tors Cellex Cell Pro­fes­sio­nals, which will con­tri­bute its expe­ri­ence in auto­ma­tion in the manu­fac­ture of medi­cal pro­ducts, and Murr­plas­tik Medi­zin­tech­nik from Fal­ken­stein, which will ensure prac­ti­cal imple­men­ta­tion with its many years of expe­ri­ence in pla­s­tics tech­no­logy in the deve­lo­p­ment and manu­fac­ture of medi­cal con­su­mer goods. TUDAG TU Dres­den Akti­en­ge­sell­schaft also par­ti­ci­pa­ted in the seed finan­cing round.

In the mar­ket seg­ment to be ser­ved by Conn­Cons GmbH, no signi­fi­cant inno­va­tion has taken place for many years. Thus, there is an oppor­tu­nity to »revo­lu­tio­nize« the mar­ket with the com­bi­na­tion of medi­cal know­ledge and expe­ri­ence from infor­ma­tion tech­no­logy, to serve large, inter­na­tio­nally exis­ting mar­kets and to par­ti­ci­pate in a lucra­tive market.